RecruitingNCT06258668
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
Sponsor
Bristol-Myers Squibb
Enrollment
505 participants
Start Date
Aug 21, 2024
Study Type
OBSERVATIONAL
Summary
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Eligibility
Min Age: 19 Years
Inclusion Criteria4
- Adult participants ≥19 years of age
- Diagnosis of moderate-to-severe plaque psoriasis
- Candidate for phototherapy or systemic therapy
- Will begin deucravacitinib according to approved product label
Exclusion Criteria2
- Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
- Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDeucravacitinib
As per product label
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06258668